Today we are delighted to announce the further expansion of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner for our Axiomer technology.
Partnerships in our industry are very common as companies look to benefit from knowledge and resource sharing. In this blog we explore why companies, like ProQR, partner with other companies.
Partnership focused on utilizing Axiomer™ to develop editing oligonucleotides targeting an underlying genetic variant that causes Rett syndromeCollaboration expands ProQR’s commitment to advance the development of therapies for central nervous system diseases
ProQR Therapeutics is a biotechnology company listed on NASDAQ with offices in Leiden, the Netherlands and Cambridge, Massachusetts, USA. ProQR is focused on the development of life-changing RNA therapies to meet the unmet needs of individuals and families with common and rare diseases.
ProQR Therapeutics is a biotechnology company listed on NASDAQ with offices in Leiden, the Netherlands, and Cambridge, Massachusetts, USA. ProQR is focused on the development of life-changing RNA therapies to meet the unmet need of individuals and families with common and rare diseases.